Mental disorders in times of hormonel changes in woman - A selective review;Psychische störungen in zeiten hormonaler umstellung bei frauen - Eine selektive übersicht

Neuropsychiatrie

Volumn 20, Issue 3, 2006, Pages 155-165

  Riecher Rössler, Anita ^a   Kuhl, Herbert ^b   Bitzer, Johannes ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Depression; Menopause; Menstrual cycle; Oestrogens; Postpartum period; Schizophrenia

Indexed keywords

ESTRADIOL; ESTROGEN; SEX HORMONE;

CLIMACTERIUM; CONFERENCE PAPER; GYNECOLOGY; HORMONE SUBSTITUTION; HUMAN; LIFE CYCLE; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MENTAL DISEASE; MOOD DISORDER; PROPHYLAXIS; PSYCHIATRIST; PUBERTY; PUERPERAL DEPRESSION; RISK FACTOR; SCHIZOPHRENIA; TREATMENT INDICATION; WELLBEING;

EID: 33845235414     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (96)

1. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 363, 419-427 (2003).
2. Manson J. E., J. Hsia, K. C. Johnson, J. E. Rossouw, A. R. Assaf, N. L. Lasser, M. Trevisan, H. R. Black, S. R. Heckbert, R. Detrano, O. L. Strickland, N. D. Wong, J. R. Crouse, E. Stein, M. Cushman: Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med 349, 523-534 (2003).
3. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. Kotchen, J. Ockene: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
4. Chlebowski R. T., S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, J. Khandekar. H. Petrovitch, A. McTiernan: Influence of estrogen plus progestin on breast cancer and mammography in healthy post-inenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289, 3243-3253 (2003).
5. Anderson G. L., M. Limache,r A. R. Assaf, T. Bassford, S. A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendri,x B. V. Howard, J. Hsia, A. Hubbell, R. Jackson, K. C. Johnson, H. Judd, J. M. Kotchen, L. Kulle,r A. Z. LaCroix, D. Lan,e R. D. Langer, N. Lasser, C. E. Lewis, J. Manson, K. Margolis, J. Ockene, M. J. O'Sullivan, L. Phillips, R. L. Prentice, C. Ritenbaugh, J. Robbins, J. E. Rossouw, G. Sarto, M. L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, S. Wassertheil-Smoller: Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
6. Genazzani A. R., M. Gambacciani, T. Simoncini, H. P. G. Schneider: "Controversial issues in climacteric medicine" series 3rd Pisa workshop "HRT in climacteric and aging brain". Pisa, Italy, 15-18 March 2003. Maturitas 46, 7-26 (2003).
7. Genazzani A. R., M. Gambacciani, H. P.G. Schneider, C. Christiansen: Post-menopausal osteoporosis: therapeutic options. Climacteric. 8, 99-109 (2005).
8. Birkhäuser M.: Was bedeuten die Resultate der Women's-Health- Initiative zur Hormonersatztherapie für die tägliche klinische Arbeit? Schweiz Med Forum 5, 379-388 (2005).
9. Birkhäuser M.: The Women's Health Initiative Conundrum. Archives of Women's Mental Health 8, 7-14 (2005).
10. The Writing Group of the IMS Executive Committee: Guidelines for hormone treatment of women in the menopausal transition and beyond. Position Statement by the Executive Committee of the International Menopause Society. Maturitas 51, 15-20 (2005).
11. Yonkers K.A.: Oestrogens, progestins and mood. In: Steiner M., K.A Yonkers, E. Eriksson: Mood disorders in women. Martin Dunitz, London 2000.
12. Bergemann N., A. Riecher-Rössler: Estrogen Effects in Psychiatric Disorders. Springer, Wien 2005.
13. Rieder A.: Genderforschung und Sozialmedizin/Public Health. Neuropsychiatrie 17 (3+4), 91-97 (2003).
14. Cyr M., F. Calon, M. Morissette, T. Di Paolo: Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 27, 12-27 (2002).
15. Goldstein J. M., L. J. Seidman, L. M. O'Brien, N. J. Norton, D. N. Kennedy, N. Makris V. S. Caviness Jr., S. V. Faraone, M. T. Tsuang: Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch. Gen. Psychiatry 59, 154-164 (2002).
16. Oesterlund M.K.: The role of estrogens in neuropsychiatric disorders. Current Opinion in Psychiatry 15, 307-312 (2002).
17. Riecher-Rössler A.: Oestrogens and schizophrenia. Current Opinion in Psychiatry 16, 187-192 (2003).
18. Vedder H., C. Behl: Estrogens in neuropsychiatric disorders: From Physiology to Pathophysiology. In: Bergemann N., A. Riecher-Rössler: Estrogen effects in psychiatric disorders. Springer, Wien 2005.
19. Garcia-Segura L. M., I. Azcoitia, L. L. DonCarlos: Neuroprotection by estradiol. Prog. Neurobiol. 63, 29-60 (2001).
20. McEwen B. S.: Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J. Appl. Physiol 91, 2785-2801 (2001).
21. Stahl S. M.: Effects of estrogen on the central nervous system. J. Clin. Psychiatry 62, 317-318 (2001).
22. Stahl S. M.: Why drugs and hormones may interact in psychiatric disorders. J. Clin. Psychiatry 62, 225-226 (2001).
23. Oesterlund M.K., Keller E., Hurd Y.L.: The human forebrain has discrete estrogen receptor a messenger RNA expression: high levels in the amygdaloid complex. Neuroscience 95, 333-342 (2000).
24. Riecher-Rössler A.: Estrogens and Schizophrenia. In: Bergemann N., A. Riecher-Rössler: Estrogen Effects in Psychiatric Disorders. Springer, Wien 2005.
25. Kahn L., U. Halbreich:: Estrogen's effect on depression. In: Bergemann N., A. Riecher-Rössler: Estrogen effects in psychiatric disorders. Springer, Wien 2005.
26. Carlson L. E., B. B. Sherwin, M.H. Chertkow:: Relationship between mood and estradiol (E-2) levels in Alzheimer's disease (AD) patients. J Gerontol B Psychol Sci Soc Sci 55, 47-53 (2000).
27. Carlson L. E., B. B. Sherwin: Relationship among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women. Neurobiol Aging 20, 315-324 (1999).
28. Wolf O. T., N.C. Schommer, D. H. Hellhamer, B. S. McEwen, C. Kirschbaum: The relationship between stress induced cortisol levels and memory differs between men and women. Psychoneuroendocrinology 26, 711-720 (2001).
29. Hogervorst E., J. Williams, M. Budge, W. Riedel, J. Jolles : The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a metaanalysis. Neuroscience 101, 485-512 (2000).
30. Fink G., B. E. Sumner, R. Rosie, O. Grace, J. P. Quinn: Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol. Neurobiol. 16, 325-344 (1996).
31. Kuhl H.: Psychoendokrinologische Einflussfaktoren. In: Riecher-Rössler A., J. Bitzer: Frauengesundheit. Ein Leitfaden für die ärztliche und psychotherapeutische Praxis. Elsevier Urban & Fischer, München 2005.
32. Archer J. S.: Relationship between estrogen, serotonin, and depression. Menopause 6, 71-78 (1999).
33. Burt, V. K., K. Stein: Epidemiology of depression throughout the female life cycle. J. Clin. Psychiatry 63, Suppl 7 9-15 (2002).
34. Cairney, J., T. J. Wade: The influence of age on gender differences in depression: further population-based evidence on the relationship between menopause and the sex difference in depression. Soc. Psychiatry Psychiatr. Epidemiol. 37, 401-408 (2002).
35. Bitzer J. A. Riecher-Rössler. Was sind Frauenleiden? Epidemiologische Aspekte. In: Riecher-Rössler A., J. Bitzer: Frauengesundheit. Ein Leitfaden für die ärztliche und psychotherapeutische Praxis. Elsevier Urban & Fischer, München 2005.
36. Wiklund I., J. Karlberg, L. A. Mattsson: Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168, 824-830 (1993).
37. Baumgartner S.: Sind geschlechtsspezifische Aspekte in der Diagnostik und Behandlung der schizophrenen Erkrankungen relevant? Neuropsychiatrie17 (3+4), 134-140 (2003).
38. Hammerbäck S., J. E. Damber, T. Bäckström: Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 68, 125-130 (1989).
39. Rubinow D. R., P. J. Schmidt: The neuroendocrinology of menstrual cycle mood disorders. Ann NY Acad Sci 771, 648-659 (1995).
40. Riecher-Rössler A: Die Spätschizophrenie - eine valide Entität? Eine empirische Studie zu Risikofaktoren, Krankheitsbild und Verlauf. Habilitationsschrift. (1994). Universität Heidelberg-Mannheim.
41. Riecher-Rössler A.: Die Mutter mit post-partaler psychischer Erkrankung - Blues, Depression, Psychose. In: Riecher-Rössler A., J. Bitzer: Frauengesundheit. Ein Leitfaden für die ärztliche und psychotherapeutische Praxis. Elsevier Urban & Fischer, München 2005.
42. Riecher-Rössler A., A. Rohde: Diagnostic classification of perinatal mood disorders. In: Riecher-Rössler A., M. Steiner: Perinatal Stress, mood and anxiety disorders. From bench to bedside. Bibliotheca Psychiatrica Nr. 173, Karger Verlag, Basel 2005.
43. Kohl C.: Generationspsychosen: Die Reaktionen von Frauen und Männern auf Schwangerschaft, Wochenbett und Stillzeit. Neuropsychiatrie 17 (3+4), 130-133 (2003).
44. Block M., P. J. Schmidt, M. Danaceau, J. Murphy, L., Nieman, D. R. Rubinow: Effects of gonadal steroids in women with a history of postpartum depression. Am. J. Psychiatry 157, 924-930 (2000).
45. Gregoire, A. J., R. Kumar, B. Everitt, A. F. Henderson, J. W. Studd: Transdermal oestrogen for treatment of severe postnatal depression. Lancet 347, 930-933 (1996).
46. Ahokas A., J. Kaukoranta, K. Wahlbeck, M. Aito: Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J. Clin. Psychiatry 62, 332-336 (2001).
47. Ahokas A. J., S. Turtiainen, M. Aito: Sublingual oestrogen treatment of postnatal depression. Lancet 351, 109 (1998).
48. Ahokas A., M. Aito, S. Turtiainen: Association between oestradiol and puerperal psychosis. Acta Psychiatr. Scand. 101, 167-169 (2000).
49. Sichel D. A., L. S. Cohen, L. M. Robertson, A. Ruttenberg, J. F. Rosenbaum: Prophylactic estrogen in recurrent post-partum affective disorder. Biol Psychiatry 38, 814-818 (1995).
50. Hunter M: The south-east England longitudinal study of the climacteric and postmenopause. Maturitas 14(2), 157-160 (1992).
51. Avis N. E., D. Brambilla, S. M. McKinlay, K. Vass: A longitudinal analysis of the association between menopause and depression. Result from the Masachusetts Women's Health Study. Ann Epidemiol 4, 214-220 (1994).
52. Dennerstein I., E. Dudley, H. Burger: Well-being and the menopausal transition. J Psychosom Obstet Gynecol 18, 95-101 (1997).
53. Woods N., A. Mariella, E. Mitchell: Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 81, 623-632 (2002).
54. Guthrie J. R., L. Dennerstein, J. R. Taffe, P. Leherl, H. G. Burger: The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 7(4), 375-389 (2004).
55. Joffe H., C. N. Soares, L. S. Cohen: Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin. North Am. 26, 563-580 (2003).
56. Zweifel J. E., W. H. O'Brien: A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22, 189-212 (1997).
57. de Noaves Soares C., O. P. Almeida, H. Joffe, L. S. Cohen: Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Archives of General Psychiatry 58, 529-534 (2001).
58. Rasgon N. L., G. W. Small, P. Siddarth, K. Miller, L. M. Ercoli, S. Y. Bookheimer, H. Lavretsky, S. C. Huang, J. R. Barrio, M. E. Phelps: Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Research: Neuroimaging Section 107, 11-18 (2001).
59. Schmidt P.J., L. Nieman, M. A. Danaceau, M. B. Tobin, C. A. Roca, J. H. Murphy, D. R. Rubinow: Estrogen replacement in perimenopause-related depression: a preliminary report. American Journal of Obstetrics and Gynecology 183, 414-420 (2000).
60. Cohen L. S., C. N. Soares, J. R. Poitras, J. Prouty, A. B. Alexander, J. L. Shifren: Short-term use of estradiol for depression in perimenopausal and post-menopausal women: a preliminary report. Am. J. Psychiatry 160, 1519-1522 (2003).
61. Krafft-Ebing G.: Untersuchungen über Irresein zur Zeit der Menstruation: Ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch Psychiatry 8, 65-107 (1896).
62. Kraepelin E.: Psychiatrie, Vol. 1-4, Barth, Leipzig 1909.
63. Kretschmer E.: Körperbau und Charakter. Untersuchungen zum Konstitution-sproblem und zur Lehre von den Temperamenten. Springer, Berlin, Heidelberg, New York 1921.
64. Bleuler M.: Die spätschizophrenen Krankheitsbilder. Neurology 15, 259-290 (1943).
65. Riecher-Rössler A., H. Häfner: Schizophrenia and Ocstrogens - is there an association? Eur Arch Psychiatry Clin Neurosci 242, 323-328 (1993).
66. Riecher-Rössler A.: Oestrogene und gonadale Achse - Implikationen für die Therapie von Frauen mit Schizophrenien. Nervenarzt 74, 398-405 (2003).
67. Cohen R. Z., M. V. Seeman, A. Gotowiec, L. Kopala: Earlier puberty as a predictor of later onset of schizophrenia in women. Am. J. Psychiatry 156, 1059-1064 (1999).
68. Häfner H., K. Maurer, W. Löffler, W. ander Heiden, P. Munk-Jørgensen, M. Hambrecht, A. Riecher-Rössler: The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol 33, 380-386 (1998).
69. Riecher A., K. Maurer, W. Löffler, B. Fätkenheuer, W. an der Heiden, P. Munk-Jørgensen, E. Strömgren, H. Häfner: Gender differences in age at onset and course of schizophrenic disorders. In: Häfner H., W. F. Gattaz: Search for the causes of schizophrenia. Vol. 2. Springer, Berlin, Heidelberg 1990.
70. Seeman M.V.: Interaction of sex, age and neuroleptic dose. Comprehensive Psychiatry 24, 125-128 (1983).
71. Szymanski S., J. A. Lieberman, J. M. Alvir, D. Mayerhoff, A. Loebel, S. Geisler, M. Chakos, A. Koreen, D. Jody, J. Kane .: Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry 152, 698-703 (1995).
72. Gattaz W.F., P. Vogel, A. Riecher-Rössler, G. Soddu: Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry 36, 137-139 (1994).
73. Bergemann N., Ch. Mundt, P. Parzer, B. Runnebaum, F. Resch: Hypoestrogenism and Estrogen Replacement Therapy in Women Suffering from Schizophrenia. In: Bergemann N., A. Riecher-Rössler: Estrogen Effects in Psychiatric Disorders. Springer, Wien 2005.
74. Riecher-Rössler A., H. Häfner, M. Stumbaum, K. Maurer, R. Schmidt: Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 20, 203-214 (1994).
75. Hallonquist J. D., M. V. Seeman, M. Lung, N. A. Rector: Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 33, 207-209 (1993).
76. Chang S. S., D. C. Renshaw: Psychosis and pregnancy. Comprehensive Therapy 12, 36-41 (1986).
77. Davies A., R. J. McIvor, R.Ch. Kumar: Impact of childbirth on a scries of schizophrenic mothers: a comment on the possible influence of oestrogen on schizophrenia. Schizophrenia Research 16, 25-31 (1995).
78. Kendell R. E., J. C. Chalmers, C. Platz: Epidemiology of puerperal psychoses. Br. J. Psychiatry 150, 662-673 (1987).
79. Riecher-Rössler A., W. Rössler: The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective. Eur. Arch. Psychiatry Clin. Neurosci. 248, 189-202 (1998).
80. Riecher-Rössler A., W. Löffler, P. Munk-Jörgensen: What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247, 195-208 (1997).
81. Mahe V., A. Dumaine: Oestrogen withdrawal associated psychoses. Acta Psychiatr. Scand. 104, 323-331 (2001).
82. Mall G.: Neuere Ergebnisse der Psycho-Endokrinologie. Aerztliche Praxis XI, 1357-1360 (1959).
83. Mall G.: Diagnostik und Therapie ovarieller Psychosen. Zentralblatt für die gesamte Neurologie und Psychiatrie 155, 250 (1960).
84. Kulkarni J., A. de Castella, D. Smith, J. Taffe, N. Keks, D. Copolov: A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research 20, 247-252 (1996).
85. Kulkarni J., A. Riedel, A. R. de Castella, P. B.Fitzgerald, T. J. Rolfe, J. Taffe, H. Burger: Estrogen - a potential treatment for schizophrenia. Schizophr Res 48, 137-144 (2001).
86. Lindamer L. A., J. B. Lohr, M. J. Harris, D. V. Jeste.: Gender, estrogen, and schizophrenia. Psychopharmacology Bulletin 33, 221-228 (1997).
87. Bergemann N., C. Mundt, P. Parzer, M. Pakrasi, U. Eckstein-Mannsperger, S. Haisch, B. Salbach, K. Klinga, B. Runnebaum, F. Resch: Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 74, 125-134 (2005).
88. Bergemann N., C. Mundt, P. Parzer, I. Jannakos, I. Nagl, B. Salbach, K. Klinga, K. Runnebaum, F. Resch: Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr. Res. 73, 357-366 (2005).
89. Kuhl H., Stevenson J.: The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits - an attempt to interpret the WHI results. Gynecol Endocrinol 22, 303-317 (2006).
90. Frank E., V. J. Grochocinski, C. A. Spanier, D.J. Buysse, C.R. Cherry, P. R. Houck, D. M. Stapf, D. J. Kupfer: Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry 61, 51-57 (2000).
91. Loprinzi C. L., J. A. Sloan, E. A. Pere,z S. K. Quella, P. J. Stella, J. A. Mailliard, M. Y. Halyard, S. Pruthi, P. J. Novotny, T. A. Rummans: Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20, 1578-1583 (2002).
92. Stearns V., K. L. Beebe, M. Iyengar, E. Dube: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289, 2827-2834 (2003).
93. Harlow B. L., L. A. Wise, M. W. Otto, C. N. Soares, L. S. Cohen: Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch. Gen. Psychiatry 60, 29-36 (2003).
94. Braendle W., M. Breckwoldt, H. Kuhl, A. Riecher-Rössler, A. Rohde, E. Rüther: Sexualhormone und Psyche - Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption. Frauenarzt 42, 154-160 (2001).
95. Davis S.R.: The effects of tibolone on mood and libido. Menopause 9, 162-170 (2002).
96. Schmidt P. J., R. C. Daly, M. Bloch, M. J. Smith, M. A. Danaceau, L. S. St Clair, J. H. Murphy, N. Haq, D. R. Rubinow: Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry 62, 154-162 (2005).